TABLE 2.
Overall, clinical, and mycological responses at EOT classified by baseline drug MICs for Aspergillus sp. isolates alone or with other fungal pathogens: CLSI and EUCAST methodologiesaa
| Methodology, treatment, and target |
Outcome | No. of isolates with indicated MIC (μg/ml)/total no. of isolates (% of total)b |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | >16 | ||
| CLSI | |||||||||
| Isavuconazole | |||||||||
| Aspergillus spp. only | Overall success | 4/9 (44) | 5/9 (56) | 6/15 (40) | 3/7 (43) | 3/6 (50) | 1/2 (50) | 0/1 | |
| Clinical success | 6/9 (67) | 9/9 (100) | 9/15 (60) | 5/7 (71) | 4/6 (67) | 2/2 (100) | 0/1 | ||
| Mycological success | 4/9 (44) | 6/9 (44) | 7/15 (47) | 3/7 (43) | 3/6 (50) | 1/2 (50) | 0/1 | ||
| Multiple fungal spp.c | Overall success | 0/1 | 0/1 | 1/3 (33) | 0/1 | ||||
| Clinical success | 1/1 (100) | 0/1 | 2/3 (67) | 0/1 | |||||
| Mycological success | 1/1 (100) | 0/1 | 1/3 (33) | 0/1 | |||||
| Voriconazole | |||||||||
| Aspergillus spp. only | Overall success | 0/1 | 1/5 (20) | 7/11 (64) | 1/5 (20) | ||||
| Clinical success | 0/1 | 2/5 (40) | 10/11 (91) | 2/5 (40) | |||||
| Mycological success | 0/1 | 1/5 (20) | 8/11 (73) | 1/5 (20) | |||||
| Multiple fungal spp.d | Overall success | 1/1 (100) | |||||||
| Clinical success | 1/1 (100) | ||||||||
| Mycological success | 1/1 (100) | ||||||||
| EUCAST | |||||||||
| Isavuconazole | |||||||||
| Aspergillus spp. only | Overall success | 4/8 (50) | 4/7 (57) | 6/16 (38) | 5/12 (42) | 1/3 (33) | 2/2 (100) | 0/1 | |
| Clinical success | 5/8 (63) | 7/7 (100) | 11/16 (69) | 8/12 (67) | 2/3 (67) | 2/2 (100) | 0/1 | ||
| Mycological success | 4/8 (50) | 4/7 (57) | 8/16 (50) | 5/12 (42) | 1/3 (33) | 2/2 (100) | 0/1 | ||
| Multiple fungal spp.c | Overall success | 0/1 | 1/1 (100) | 0/1 | 0/1 | 0/1 | 0/1 | ||
| Clinical success | 1/1 (100) | 1/1 (100) | 0/1 | 1/1 (100) | 0/1 | 0/1 | |||
| Mycological success | 1/1 (100) | 1/1 (100) | 0/1 | 0/1 | 0/1 | 0/1 | |||
| Voriconazole | |||||||||
| Aspergillus spp. only | Overall success | 3/10 (30) | 5/8 (63) | 1/3 (33) | 0/1 | ||||
| Clinical success | 6/10 (60) | 6/8 (75) | 2/3 (67) | 0/1 | |||||
| Mycological success | 4/10 (40) | 5/8 (63) | 1/3 (33) | 0/1 | |||||
| Multiple fungal spp.d | Overall success | 1/1 (100) | |||||||
| Clinical success | 1/1 (100) | ||||||||
| Mycological success | 1/1 (100) | ||||||||
See the supplemental materials for responses for individual and multiple Aspergillus spp. CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; EOT, end of treatment.
The denominator represents the number of patients whose isolates had that drug MIC (where patients had multiple isolates, the isolate with the highest baseline drug MIC was used); the numerator denotes the number of patients who demonstrated a response of success.
Data include Lichtheimia corymbifera (n = 2 patients), Fonsecaea monophora, Chaetomium brasiliense, and Rhizopus oryzae.
Data include Penicillium piceum.